Question 1

What is Reproxalap?

Accepted Answer

Reproxalap is a Other.

Question 2

How often does Reproxalap appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 80 articles.

Question 3

When was Reproxalap first tracked by Ergen?

Accepted Answer

First tracked on Apr 24, 2026.

Question 4

When was Reproxalap last mentioned in news?

Accepted Answer

Last active on Jun 09, 2026.

Question 5

What is Reproxalap's current news sentiment?

Accepted Answer

Aggregate sentiment score: -80 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Reproxalap in global news coverage?

Accepted Answer

Attention score of 6, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving Reproxalap?

Accepted Answer

Aldeyra Therapeutics Faces Class Actions (Apr 24, 2026, 80 articles).

Question 8

How did the "Aldeyra Therapeutics Faces Class Actions" event impact Reproxalap?

Accepted Answer

Reproxalap is an investigational drug candidate by Aldeyra Therapeutics for dry eye disease, which failed to receive United States — Food and Drug Administration approval, leading to the company's stock decline and the class action lawsuit.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.